DRIO does have a viable product but it is being released into a very saturated blood glucose testing market. IF Dario provides a better user experience than what's currently on the market than the CEO's prediction of 3% market share could be realized.
I'll wait for the necessary raise in A/S and further dilution before I jump back in. A R/S will be required but it won't be proportional to the O/S so further dilution is a given IMO.